HCW Biologics Inc. 8-K

What Happened

• HCW Biologics Inc. (HCWB) filed an 8‑K reporting that on February 17, 2026 it signed a Securities Purchase Agreement with a single institutional investor to sell 2,477,292 units in a follow‑on offering. The offering closed on February 19, 2026 and was registered on an S‑1 declared effective February 17, 2026.
• Each unit consists of either one share of common stock (or, in lieu of a share, one Pre‑Funded Warrant) plus one Common Stock Purchase Warrant. Gross proceeds to the company are approximately $1.5 million before fees and expenses.

Key Details

• Units sold: 2,477,292 units.
• Pricing: $0.6055 per unit for (one share + Common Warrant); $0.6054 per unit for (one Pre‑Funded Warrant + Common Warrant).
• Warrants: Pre‑Funded Warrants exercise price $0.0001 (exercisable immediately; no expiration until fully exercised). Common Warrants exercise price $0.6055, exercisable only upon stockholder approval and expire five years after such approval.
• Existing warrants: The investor holds Prior Warrants to buy up to 3,020,410 shares; HCW entered an agreement to seek shareholder approval to reduce those exercise prices to the Offering price (no assurance approval will be obtained).
• Placement agent: Maxim Group LLC, fee equal to 6.9% of gross proceeds plus reimbursement of out‑of‑pocket expenses (including legal fees capped at $65,000).

Why It Matters

• The transaction raises modest cash (~$1.5M) to the company but also brings a significant number of warrants and potential future dilution if warrants are exercised or if existing warrants are amended to a lower exercise price.
• Common Warrants are conditional on shareholder approval under Nasdaq rules, so the timing and final dilution impact depend on whether stockholders approve the proposed amendment to existing warrants.
• Investors should note the placement fee (6.9%) and expense reimbursements reduce net proceeds, and that Pre‑Funded Warrants allow immediate settlement in many cases while Common Warrants may only become exercisable after approval.